Skip to main content

Advertisement

Table 2 Comparison of the percentages of γδ T cell subsets between untreated MS patients, IFN-β-treated MS patients, and healthy controls

From: Long-term use of interferon-β in multiple sclerosis increases Vδ1Vδ2Vγ9 γδ T cells that are associated with a better outcome

  Untreated MS (n = 35) MS w/ IFN-β (n = 21) HCs (n = 44) p value (K-W test) padj value
Untreated MS vs. HCs MS w/ IFN-β vs. HCs Untreated MS vs. MS w/ IFN-β
Vδ1+ 29.0 (14.0–53.9) 29.6 (13.7–48.3) 18.4 (11.6–34.2) NS
 Vδ1+Vγ9+ 3.91 (1.26–10.2) 3.00 (1.60–5.17) 2.15 (1.12–4.71) NS
 Vδ1+Vγ9 24.3 (10.2–40.8) 23.5 (10.0–38.3) 15.5 (8.47–31.5) NS
Vδ2+ 32.9 (13.3–52.3) 21.2 (5.07–33.4) 54.9 (31.7–65.9) < 0.001 0.047 < 0.001 0.017
 Vδ2+Vγ9+ 32.7 (12.9–52.2) 21.1 (4.70–32.1) 54.3 (31.1–65.7) < 0.001 0.043 < 0.001 0.016
 Vδ2+Vγ9 0.16 (0.07–0.46) 0.16 (0.00–0.44) 0.08 (0.03–0.29) NS
Vδ1Vδ2 22.8 (15.5–39.5) 35.6 (27.1–58.2) 22.8 (17.1–30.3) 0.001 NS < 0.001 0.002
 Vδ1Vδ2Vγ9+ 1.23 (0.36–2.91) 1.10 (0.33–2.53) 2.42 (1.25–3.83) 0.010 NS 0.009 NS
 Vδ1Vδ2Vγ9 22.0 (14.7–36.1) 33.1 (24.5–55.3) 18.1 (10.7–26.4) < 0.001 NS (0.073) < 0.001 < 0.001
  1. Values are the median (IQR). Percentages of each population in total γδ T cells are shown
  2. p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then padj values were calculated using multivariate linear regression analyses adjusted for age and sex
  3. HCs healthy controls, IFN-β interferon-β, IQR interquartile ranges, K-W Kruskal-Wallis, MS multiple sclerosis, NS not significant, w/ with